Archives of Neurology · 2008 · 194 citations · 23 references
Life SciencesNeurologyNeuroscienceMolecular NeuroscienceNeurodegenerationNeuropathologyAmyotrophic Lateral SclerosisBiomarkers Of NeurodegenerationCerebrospinal Fluid BiomarkersMotor Neuron DiseasesNeurodegenerative DiseasesNeurodegenerative DisordersAmyotrophic Lateral Sclerosis PathologyCerebrospinal Fluid Neurodegeneration MarkersDifferential Diagnostic CriteriaGlial Cytoplasmic InclusionsOutcome MeasuresPolyclonal AntibodiesTar Dna-binding Protein 43 PathologyTdp-43 Pathology
BACKGROUND: Recently, TAR DNA-binding protein 43 (TDP-43) was identified as the major component of ubiquitin-positive tau-negative neuronal and glial inclusions in the most common form of frontotemporal lobar degeneration (FTLD) and in amyotrophic lateral sclerosis (ALS). It was demonstrated that different TDP-43 profiles correspond to clinical phenotypes of FTLD or ALS subgroups, and the differential diagnostic potential of TDP-43 was suggested. OBJECTIVES: To examine TDP-43 in cerebrospinal fluid (CSF) and to analyze whether it could serve as a diagnostic marker. DESIGN: We characterized CSF TDP-43 by immunoblot using different TDP-43 antibodies and determined the relative TDP-43 levels in CSF samples from patients. SETTING: Academic research. PATIENTS: Twelve patients with FTLD, 15 patients with ALS, 9 patients with ALS plus FTLD, 3 patients with ALS plus additional signs of frontal disinhibition, and 13 control subjects. MAIN OUTCOME MEASURES: Results of TDP-43 immunoblot. RESULTS: Polyclonal TDP-43 antibodies recognized a 45-kDa band in all analyzed samples. Two monoclonal and N-terminus-specific antibodies did not detect any specific bands, but C-terminus-specific antibodies detected a 45-kDa band and additional bands at approximately 20 kDa in all CSF samples. Relative quantification of 45-kDa bands revealed significant differences among the diagnostic groups (P =.046). Specifically, patients with ALS (P =.03) and FTLD (P =.02) had higher TDP-43 levels than controls but with a prominent overlap of values. CONCLUSION: Although there is no evidence of pathologically altered TDP-43 proteins in CSF, TDP-43 levels in CSF might aid in characterizing subgroups of patients across the ALS and FTLD disease spectrum.
23
Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 86.9K citations
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Manuela Neumann, Deepak M. Sampathu, Linda K. Kwong et al. · Science · 2006 · 6.6K citations
Tetsuaki Arai, Masato Hasegawa, Haruhiko Akiyama et al. · Biochemical and Biophysical Research Communications · 2006 · 2.8K citations
TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis
Jemeen Sreedharan, Ian P. Blair, Vineeta B. Tripathi et al. · Science · 2008 · 2.6K citations · Full text